Live Quote · NASDAQPBYIHealthcare· Biotechnology

Puma Biotechnology, Inc.

$8.26 3.38%(+$0.27)
TickerSpark Score
80/100
Strong
92
Valuation
95
Profitability
20
Growth
92
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBYI research report →

52-Week Range97% of range
Low
$3.03
Current
$8.26
High
$8.41
Company Overviewwww.pumabiotechnology.com

About the company

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications.

CEO
Alan H. Auerbach
IPO
2012
Employees
172
HQ
Los Angeles, CA, US

Price Chart

+132.02% · this period
$8.26$5.67$3.07Jul 02Dec 31Jul 02
Valuation
Market Cap
$420.43M
P/E
16.65
P/S
1.85
P/B
3.27
EV/EBITDA
8.91
Div Yield
0.00%
Profitability
Gross Margin
74.46%
Op Margin
12.98%
Net Margin
10.73%
ROE
20.37%
ROIC
17.12%
Growth & Income
Revenue
$228.37M · -0.91%
Net Income
$31.11M · 2.75%
EPS
$0.62 · 0.00%
Op Income
$37.30M
FCF YoY
7.38%
Performance & Tape
52W High
$8.41
52W Low
$3.03
50D MA
$7.35
200D MA
$6.28
Beta
1.19
Avg Volume
285.55K

Get TickerSpark's AI analysis on PBYI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 11, 26WILSON TROY EDWARDother27,000
Jun 12, 26WILSON TROY EDWARDsell10,800
Jun 11, 26Stuglik Brian Mother27,000
Jun 12, 26Stuglik Brian Msell8,100
Jun 11, 26Senderowicz Adrianother27,000
Jun 12, 26Senderowicz Adriansell27,000
Jun 11, 26MILLER MICHAEL PATRICKother27,000
Jun 11, 26MOYES JAY Mother27,000
Jun 12, 26MOYES JAY Msell22,000
Jun 11, 26Dorval Allisonother27,000
Coverage · PBYI

Our PBYI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on PBYI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate PBYI report →
Internal Compare

Similar companies

Peers in the same neighborhood.